Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 5, 2018. The report disseminates an LSE announcement regarding ViiV Healthcare, a global specialist HIV company majority-owned by GSK (with Pfizer Inc. and Shionogi Limited as shareholders). The filing focuses on interim clinical trial results rather than corporate financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of clinical study data and does not contain financial statements or key performance indicators for GSK or ViiV Healthcare.
Material Changes and Clinical Results
The primary material update concerns the INSPIRING study, a phase IIIb trial evaluating dolutegravir (Tivicay) in adults with HIV co-infected with tuberculosis (TB). Interim results at Week 24 indicate:
- Viral Suppression: 81% (56/69) of patients in the dolutegravir arm maintained viral suppression (HIV-1 RNA <50 copies/mL), compared to 89% (39/44) in the efavirenz control arm.
- Safety and Tolerability: No patients in the dolutegravir arm discontinued due to adverse events, whereas two patients in the efavirenz arm did. Discontinuations due to non-treatment reasons were 7% for dolutegravir and 0% for efavirenz.
- Resistance and IRIS: No treatment-emergent resistance was reported in the dolutegravir arm (one report in the efavirenz arm). TB-associated immune reconstitution inflammatory syndrome (IRIS) rates were low and equal in both arms (n=4), with no discontinuations due to IRIS or liver events.
Outlook, Risks, and Management Commentary
Management Commentary: John C. Pottage, Jr., MD, Chief Scientific and Medical Officer at ViiV Healthcare, emphasized that TB remains the leading cause of death among people living with HIV. He noted that the INSPIRING results support the use of dolutegravir in this underserved population, addressing challenges such as drug interactions and overlapping toxicities.
Outlook: The study is ongoing, with 48-week data expected to be presented at a future scientific meeting.
Risks and Contingencies: The filing includes standard safety warnings for Tivicay, including hypersensitivity reactions, hepatotoxicity (particularly in patients with hepatitis B or C), and potential drug interactions. GSK includes a cautionary statement that forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from projections.
Investor Verification Checklist
- Verify the final 48-week data for the INSPIRING study when presented at future scientific meetings.
- Monitor regulatory approval status for dolutegravir in HIV/TB co-infected populations across key markets.
- Review GSK's Annual Report on Form 20-F for comprehensive financial data, as this filing contains no financial metrics.
- Assess the competitive landscape for HIV/TB co-infection treatments, specifically regarding efavirenz and other integrase inhibitors.